Another Option for Ankylosing Spondylitis?

(MedPage Today) -- The Janus kinase (JAK) inhibitor tofacitinib (Xeljanz) demonstrated efficacy for ankylosing spondylitis in a phase III trial.
At week 16, a 20% improvement on the Assessment in Ankylosing Spondylitis (ASAS20) response criteria...